NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis $4.70 -0.09 (-1.88%) Closing price 03:59 PM EasternExtended Trading$4.70 +0.00 (+0.04%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Champions Oncology Stock (NASDAQ:CSBR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Champions Oncology alerts:Sign Up Key Stats Today's Range$4.70▼$4.8450-Day Range$4.77▼$5.3052-Week Range$4.59▼$8.31Volume1,844 shsAverage Volume8,881 shsMarket Capitalization$65.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Champions Oncology, Inc. is a biotechnology and technology company focused on precision oncology and the development of personalized approaches to cancer treatment. The company works with pharmaceutical and biotechnology companies, academic researchers, and healthcare providers to support the discovery, development, and evaluation of cancer therapies. Its offerings include patient-derived tumor models, including tumor avatar models, that are designed to help researchers study how individual cancers may respond to potential treatments. Champions Oncology also provides molecular profiling, bioinformatics, data analysis, and translational research services intended to connect laboratory findings with clinical development programs. The company serves customers involved in oncology drug research and development, including organizations conducting preclinical studies and clinical trials. Its business is centered on applying patient-specific tumor data and analytics to support therapy selection, biomarker research, combination-treatment studies, and broader efforts to develop more targeted cancer treatments.AI Generated. May Contain Errors. Read More Champions Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreCSBR MarketRank™: 0.39658765303 of 5 starsChampions Oncology scored higher than 8% of companies evaluated by MarketBeat, and ranked 859th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingChampions Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Champions Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -58.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -58.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 16.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Champions Oncology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.95% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Champions Oncology has recently increased by 3.65%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.31 News SentimentChampions Oncology has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Champions Oncology this week, compared to 2 articles on an average week. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders46.30% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Champions Oncology's insider trading history. Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CSBR Stock News HeadlinesChampions Oncology Stockholders Approve Governance and Incentive Plan3 hours ago | tipranks.comChampions Oncology (NASDAQ:CSBR) Share Price Breaks Below Two Hundred Day Moving Average - What's Next?October 13 at 2:21 AM | americanbankingnews.comDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 16 at 1:00 AM | Profits Run (Ad)Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call TranscriptSeptember 10, 2026 | seekingalpha.comChampions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026September 4, 2026 | finance.yahoo.comChampions Oncology, Inc. (CSBR) Q4 2026 Earnings Call TranscriptJuly 27, 2026 | seekingalpha.comChampions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $59 MillionJuly 27, 2026 | finanznachrichten.deChampions Oncology, Inc.: Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026April 9, 2026 | finanznachrichten.deSee More Headlines CSBR Stock Analysis - Frequently Asked Questions How have CSBR shares performed this year? Champions Oncology's stock was trading at $6.9250 at the beginning of 2026. Since then, CSBR stock has decreased by 32.1% and is now trading at $4.70. How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) announced its quarterly earnings results on Thursday, September, 10th. The biotechnology company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.06. The biotechnology company earned $15.23 million during the quarter, compared to analysts' expectations of $15.05 million. Champions Oncology had a negative trailing twelve-month return on equity of 25.77% and a negative net margin of 1.82%. Read the conference call transcript. How do I buy shares of Champions Oncology? Shares of CSBR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), Broadcom (AVGO) and Achieve Life Sciences (ACHV). Company Calendar Last Earnings9/10/2026Today10/16/2026Next Earnings (Estimated)12/15/2026Fiscal Year End4/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CSBR's financial health is in the Yellow zone, according to TradeSmith. CSBR has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CSBR CIK771856 Webwww.championsoncology.com Phone(410) 369-0365Fax410-369-0390Employees214Year Founded2007Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.17 million Net Margins-1.82% Pretax Margin-1.47% Return on Equity-25.77% Return on Assets-3.71% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$59.42 million Price / Sales1.10 Cash Flow$0.01 per share Price / Cash Flow330.67 Book Value$0.29 per share Price / Book16.21Miscellaneous Outstanding Shares13,920,000Free Float7,475,000Market Cap$65.42 million OptionableOptionable Beta0.44 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CSBR) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
